Helus PharmaHELP -3.92%22 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 705 Biotechnology companies, Helus Pharma ranks worse than 141843.83% on this metric.
The historical rank and industry rank for Helus Pharma's Days Payable or its related term are showing as below:
During the past 7 years, Helus Pharma's highest Days Payable was 1536.20. The lowest was 1536.20. And the median was 1536.20.
HELP's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.36 * Ranked among companies with meaningful Days Payable only.
Helus Pharma's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Helus Pharma Days Payable Related Terms
Helus Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Helus Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Helus Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helus Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helus Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Helus Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Helus Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helus Pharma (HELP) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Helus Pharma and its competitors. Over the past decade, Helus Pharma's Days Payable has ranged from 1,536.20 to 1,536.20. According to the industry distribution chart, Helus Pharma ranks #999999 out of 705 companies in the Biotechnology industry.
Is Helus Pharma's Days Payable too high?
Helus Pharma's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,536.20 to a high of 1,536.20. Based on the distribution chart, Helus Pharma ranks #999999 out of 705 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #999999 out of 705 companies for Days Payable. This places Helus Pharma in the lower half of its industry. The industry median Days Payable is 113.36. Historically, Helus Pharma's own Days Payable has ranged from 1,536.20 to 1,536.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Helus Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helus Pharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Days Payable of 0.00. The current Days Payable is 0.00. Helus Pharma's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Helus Pharma (HELP), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score
Get the complete analysis for HELP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HELP has been successfully added to your 
